The genetic basis of cancer is increasingly understood, driving significant advancements in personalized medicine.  Cancer arises from somatic mutations accumulating within a cell, disrupting crucial cellular processes like growth control and apoptosis.  Advances in genomic sequencing technologies, particularly next-generation sequencing (NGS), allow for comprehensive profiling of tumor genomes, identifying specific driver mutations and characterizing the tumor's unique molecular signature. This information is crucial for targeted therapies. For example, identifying EGFR mutations in lung cancer enables the prescription of EGFR tyrosine kinase inhibitors, offering significantly improved outcomes compared to generic chemotherapy. Similarly, the identification of specific translocation events, like the BCR-ABL fusion in chronic myeloid leukemia, guides the use of tyrosine kinase inhibitors like imatinib, demonstrating the power of precision oncology.  Furthermore, understanding the tumor's microenvironment, including its immunologic profile, through genomic and transcriptomic analysis, facilitates immunotherapy selection, maximizing the effectiveness of immune checkpoint inhibitors.  These personalized approaches, while still facing challenges in terms of cost and access, represent a paradigm shift in cancer treatment, moving from a one-size-fits-all approach towards tailored therapies based on a patient's unique genetic landscape.